Dizal's sunvozertinib beats chemotherapy in Phase III first-line EGFR exon 20 insertion NSCLC trial

Dizal (SSE:688192) reported that its Phase III WU-KONG28 trial of sunvozertinib (Zegfrovy) met its primary endpoint in first-line NSCLC harboring EGFR exon 20 insertion mutations, with the oral EGFR inhibitor delivering a statistically significant improvement in progression-free survival over platinum-based chemotherapy. The result positions sunvozertinib as the first targeted monotherapy to demonstrate a PFS benefit against chemotherapy in this mutation-defined population in a randomized Phase III setting.

WU-KONG28 is a multinational, open-label, randomized Phase III trial conducted across 16 countries comparing once-daily oral sunvozertinib monotherapy to investigator-choice platinum-containing doublet chemotherapy in treatment-naive patients with advanced NSCLC driven by EGFR exon 20 insertion mutations. PFS, assessed by blinded independent central review, served as the primary endpoint.

Dizal disclosed that sunvozertinib achieved a statistically significant and clinically meaningful PFS advantage over chemotherapy. The company also stated that all prespecified secondary endpoints, including confirmed objective response rate, duration of response, and disease control rate, favored the sunvozertinib arm. Specific numerical results for PFS and secondary endpoints were not disclosed; the company said detailed data will be submitted for presentation at an upcoming scientific congress. Sunvozertinib was generally well tolerated, with a safety profile consistent with earlier studies. The most common treatment-emergent adverse events were Grade 1 or 2 in severity, according to the company.

Sunvozertinib is an irreversible, oral small-molecule EGFR tyrosine kinase inhibitor designed to selectively target mutant EGFR while sparing wild-type receptor activity. EGFR exon 20 insertion mutations represent approximately 1–2% of all NSCLC cases and have historically been resistant to first- and second-generation EGFR inhibitors such as erlotinib and afatinib. The structural heterogeneity of these insertions, with over 100 identified subtypes, has made drug design against this target class particularly difficult, and patients have until now relied on platinum-based chemotherapy as first-line treatment.

Sunvozertinib already holds approvals in both the United States and China for adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy. The U.S. approval was supported by the multinational WU-KONG1 Part B study, while the China approval drew on the WU-KONG6 trial. Johnson & Johnson's amivantamab (Rybrevant), a bispecific antibody targeting EGFR and MET, and Takeda's mobocertinib were both approved in the second-line exon 20 insertion setting, though Takeda voluntarily withdrew mobocertinib from the U.S. market in 2023 after a confirmatory trial failed to meet its primary endpoint. Amivantamab in combination with chemotherapy has been studied in earlier lines of therapy for broader EGFR-mutant populations, but no targeted agent had previously demonstrated a Phase III PFS benefit as monotherapy versus chemotherapy in the first-line exon 20 insertion setting specifically. Cross-trial comparisons are limited by differences in study design, patient populations, and endpoints.

The WU-KONG28 result is therefore notable for establishing, in a controlled setting, that a chemotherapy-free oral regimen can outperform the existing standard of care for a patient population with limited targeted treatment options. Sunvozertinib has received Breakthrough Therapy Designation from both the U.S. FDA and China's Center for Drug Evaluation for the first-line exon 20 insertion indication, which may facilitate regulatory review timelines. Dizal said it plans to engage with regulatory authorities regarding potential new drug applications based on the WU-KONG28 data.

---

Spot something wrong? Report an issue with this article